Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double …
L Webster, JP Jansen, J Peppin, B Lasko, G Irving… - PAIN®, 2008 - Elsevier
Our objective was to investigate the efficacy and safety of alvimopan, a peripherally acting
mu-opioid receptor (PAM-OR) antagonist, in subjects with non-cancer pain and opioid-
induced bowel dysfunction (OBD), and to identify at least one treatment regimen that
improves OBD. Following a 2-week baseline period, 522 subjects reporting< 3 spontaneous
bowel movements (SBMs)/week (with⩾ 25% accompanied by a sensation of incomplete
evacuation, straining, or lumpy hard stools), requiring analgesia equivalent to⩾ 30mg oral …
mu-opioid receptor (PAM-OR) antagonist, in subjects with non-cancer pain and opioid-
induced bowel dysfunction (OBD), and to identify at least one treatment regimen that
improves OBD. Following a 2-week baseline period, 522 subjects reporting< 3 spontaneous
bowel movements (SBMs)/week (with⩾ 25% accompanied by a sensation of incomplete
evacuation, straining, or lumpy hard stools), requiring analgesia equivalent to⩾ 30mg oral …